Therapeutic areas: Rare Disease, RNAi Therapeutics
Alnylam pioneered RNA interference therapeutics and its rare disease reps cover Onpattro (TTR-hATTR amyloidosis), Givlaari (AHP), Oxlumo (PH1), and Amvuttra (a subcutaneous TTR treatment). Rare disease rep roles require exceptional clinical depth and patient advocacy skills. The company culture is widely regarded as mission-driven.
Key products: Amvuttra, Onpattro, Givlaari, Oxlumo
Alnylam pioneered RNA interference therapeutics and its rare disease reps cover Onpattro (TTR-hATTR amyloidosis), Givlaari (AHP), Oxlumo (PH1), and Amvuttra (a subcutaneous TTR treatment). Rare diseas